论文部分内容阅读
近年来,随着基因治疗技术的不断进步,为心肌缺血的治疗开辟了一条全新的途径,并取得了一些令人鼓舞的进展。基因治疗主要包括治疗基因、基因转移载体以及基因导入途径三个方面。基因转移载体又在治疗基因和基因表达之间起着桥梁作用,因此,发展安全、高效的基因转移系统是基因治疗的关键之一。目前用于基因治疗心肌缺血基因转移的载体主要有病毒载体和非病毒载体。下面将就不同载体在心肌缺血的基因治疗中的应用进展进行简要的总结。
In recent years, along with the continuous improvement of gene therapy technology, a completely new approach has been opened up for the treatment of myocardial ischemia and some encouraging progress have been made. Gene therapy mainly includes the treatment of genes, gene transfer vectors and gene transfer pathways. Gene transfer vectors, in turn, play a bridging role between gene therapy and gene therapy. Therefore, developing a safe and efficient gene transfer system is one of the keys to gene therapy. Currently used for gene therapy of myocardial ischemia gene transfer vectors mainly viral vectors and non-viral vectors. The following is a brief summary of the progress of different vectors in the gene therapy of myocardial ischemia.